Rossi David, Sarti Donatella, Malerba Lara, Tommasoni Silvia, Visani Giuseppe, Martignetti Angelo, Fiorentini Giammaria
Oncology Unit, Azienda Ospedaliera "Ospedali Riuniti Marche Nord," Pesaro - Italy.
Hematology Unit, Azienda Ospedaliera "Ospedali Riuniti Marche Nord," Pesaro - Italy.
Tumori. 2016 Nov 11;102(Suppl. 2):F987D442-1B9F-4F74-970B-FA54621C138F. doi: 10.5301/tj.5000489.
Secondary malignancies are new cancers occurring in patients previously treated with radiation or chemotherapy for a primary tumor. Secondary cancers are not related to the primary tumor, and may develop months or years after cancer treatment: they are usually a result of the first cancer therapy. Chemotherapy and radiotherapy may increase the risk of second cancers, such as skin tumors (basal or squamous cell carcinoma) or acute leukemia.
A patient with B-lymphoma and a patient with multiple myeloma, previously treated for breast cancer, are presented.
We report the cases of 2 patients treated with adjuvant therapy for breast cancer who developed secondary bone marrow malignancies 15 years after primary treatment.
By literature review, these 2 cases do not support the relationship between primary tumor treatment and secondary cancer, but strongly suggest the need for histologic samples when bone metastasis occurred after years from diagnosis of breast cancer. In this setting, the oncologist should take into account a secondary bone marrow tumor before starting treatment for breast cancer.
继发性恶性肿瘤是指先前因原发性肿瘤接受过放疗或化疗的患者所发生的新癌症。继发性癌症与原发性肿瘤无关，可能在癌症治疗数月或数年之后出现：它们通常是首次癌症治疗的结果。化疗和放疗可能会增加患继发性癌症的风险，如皮肤肿瘤（基底细胞癌或鳞状细胞癌）或急性白血病。
介绍了一名曾接受乳腺癌治疗的B淋巴瘤患者和一名曾接受乳腺癌治疗的多发性骨髓瘤患者。
我们报告了2例接受乳腺癌辅助治疗的患者，她们在初次治疗15年后发生了继发性骨髓恶性肿瘤。
通过文献回顾，这2例病例不支持原发性肿瘤治疗与继发性癌症之间的关系，但强烈提示，在乳腺癌诊断多年后发生骨转移时，需要获取组织学样本。在这种情况下，肿瘤学家在开始乳腺癌治疗前应考虑继发性骨髓肿瘤。
